These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12173980)

  • 41. Does Valproic Acid/Na Valproate Suppress Auditory Startle Reflex in Patients With Epilepsy?
    Kızıltan ME; Leba LK; Gündüz A; Pazarcı N; Özkara Ç; Yeni N
    Clin EEG Neurosci; 2018 Nov; 49(6):407-413. PubMed ID: 29262725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polycomb homologs are involved in teratogenicity of valproic acid in mice.
    Okada A; Aoki Y; Kushima K; Kurihara H; Bialer M; Fujiwara M
    Birth Defects Res A Clin Mol Teratol; 2004 Nov; 70(11):870-9. PubMed ID: 15523661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Actions of sodium valproate on the central nervous system.
    Tunnicliff G
    J Physiol Pharmacol; 1999 Sep; 50(3):347-65. PubMed ID: 10574466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of valproate derivatives I. Antiepileptic efficacy of amides, structural analogs and esters.
    Redecker C; Altrup U; Hoppe D; Düsing R; Speckmann EJ
    Neuropharmacology; 2000 Jan; 39(2):254-66. PubMed ID: 10670421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.
    Hönack D; Rundfeldt C; Löscher W
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Feb; 345(2):187-96. PubMed ID: 1570023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Morphological changes induced by valproate and its administration concomitant with folinic acid or S-adenosylmethionine in pregnant rats].
    Ubeda-Martín N; Alonso-Aperte E; Achón M; Varela-Moreiras G; Puerta J; Pérez de Miguelsanz J
    Nutr Hosp; 1998; 13(1):41-9. PubMed ID: 9578686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues.
    Walmod PS; Foley A; Berezin A; Ellerbeck U; Nau H; Bock E; Berezin V
    Cell Motil Cytoskeleton; 1998; 40(3):220-37. PubMed ID: 9678666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic and endocrine effects of valproic acid chronic treatment.
    Belcastro V; D'Egidio C; Striano P; Verrotti A
    Epilepsy Res; 2013 Nov; 107(1-2):1-8. PubMed ID: 24076030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of teratogenic potency of valproate analogues using cerebellar aggregation cultures.
    Maar TE; Ellerbeck U; Bock E; Nau H; Schousboe A; Berezin V
    Toxicology; 1997 Jan; 116(1-3):159-68. PubMed ID: 9020517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Valproate can induce reversible encephalopathy].
    Prakash S; Harbo T; Christensen J
    Ugeskr Laeger; 2014 Nov; 176(45):. PubMed ID: 25394838
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Valproate can induce reversible encephalopathy].
    Prakash S; Harbo T; Christensen J
    Ugeskr Laeger; 2015 May; 177(20):945-6. PubMed ID: 26535436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New generation of valproic acid.
    Trojnar MK; Wierzchowska-Cioch E; Krzyzanowski M; Jargiełło M; Czuczwar SJ
    Pol J Pharmacol; 2004; 56(3):283-8. PubMed ID: 15215557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.
    Duncan S; Mercho S; Lopes-Cendes I; Seni MH; Benjamin A; Dubeau F; Andermann F; Andermann E
    Epilepsia; 2001 Jun; 42(6):750-3. PubMed ID: 11422330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement.
    Gotfryd K; Owczarek S; Hoffmann K; Klementiev B; Nau H; Berezin V; Bock E; Walmod PS
    Neuropharmacology; 2007 Mar; 52(3):764-78. PubMed ID: 17095022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
    Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A
    Seizure; 2018 May; 58():90-95. PubMed ID: 29679911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives.
    Lampen A; Carlberg C; Nau H
    Eur J Pharmacol; 2001 Nov; 431(1):25-33. PubMed ID: 11716839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
    Sidhu HS; Srinivas R; Sadhotra A
    Seizure; 2017 May; 48():15-21. PubMed ID: 28365440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial interaction between vigabatrin and valproate against seizures induced by pentylenetetrazole in mice.
    Cuadrado A; Armijo JA
    Pharmacol Res; 2005 May; 51(5):489-96. PubMed ID: 15749465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate.
    Taing KD; O'Brien TJ; Williams DA; French CR
    PLoS One; 2017; 12(1):e0169974. PubMed ID: 28076384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum copper and zinc levels in epileptic children with valproate treatment.
    Kaji M; Ito M; Okuno T; Momoi T; Sasaki H; Yamanaka C; Yorifuji T; Mikawa H
    Epilepsia; 1992; 33(3):555-7. PubMed ID: 1592036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.